These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20808264)

  • 1. Effects of pravastatin on murine chronic graft-versus-host disease.
    Yoon HK; Lim JY; Kim TJ; Cho CS; Min CK
    Transplantation; 2010 Oct; 90(8):853-60. PubMed ID: 20808264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
    Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
    Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers.
    Eyrich M; Burger G; Marquardt K; Budach W; Schilbach K; Niethammer D; Schlegel PG
    Biol Blood Marrow Transplant; 2005 May; 11(5):371-82. PubMed ID: 15846291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation.
    MacDonald KP; Rowe V; Filippich C; Johnson D; Morris ES; Clouston AD; Ferrara JL; Hill GR
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):373-85. PubMed ID: 15148491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease.
    Levi-Schaffer F; Goldenhersh MA; Segal V; Nagler A
    Bone Marrow Transplant; 1997 Apr; 19(8):823-8. PubMed ID: 9134176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.
    Schultz KR; Paquet J; Bader S; HayGlass KT
    Bone Marrow Transplant; 1995 Aug; 16(2):289-95. PubMed ID: 7581150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate.
    Friedman TM; Statton D; Jones SC; Berger MA; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2001; 7(1):2-13. PubMed ID: 11215694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
    Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
    Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice.
    Nagler A; Pines M; Abadi U; Pappo O; Zeira M; Rabbani E; Engelhardt D; Ohana M; Chowdhury NR; Chowdhury JR; Ilan Y
    Hepatology; 2000 Mar; 31(3):641-8. PubMed ID: 10706554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.
    Decker CJ; Heiser AD; Chaturvedi PR; Faust TJ; Ku G; Moseley S; Nimmesgern E
    Drugs Exp Clin Res; 2001; 27(3):89-95. PubMed ID: 11447770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease.
    Levi-Schaffer F; Segal V; Barak V; Rubinchik E; Nagler A
    Exp Hematol; 1997 Mar; 25(3):238-45. PubMed ID: 9091300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease.
    Howell CD; Yoder T; Claman HN; Vierling JM
    J Immunol; 1989 Jul; 143(2):476-83. PubMed ID: 2472440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
    Wang SB; Guo KY; Hu DM; Yin B
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-phase pathogenesis of graft-versus-host disease in mice.
    van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA
    Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT.
    Urbano-Ispizua A; García-Conde J; Brunet S; Hernández F; Sanz G; Petit J; Bargay J; Figuera A; Rovira M; Solano C; Ojeda E; de la Rubia J; Rozman C
    Haematologica; 1997; 82(6):683-9. PubMed ID: 9499667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
    Ewing P; Miklos S; Olkiewicz KM; Müller G; Andreesen R; Holler E; Cooke KR; Hildebrandt GC
    Exp Hematol; 2007 Jan; 35(1):155-63. PubMed ID: 17198884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.